AbTherx has launched a platform to discover a new generation of antibodies
AbTherx, a privately held biotechnology company pacing up the discovery of antibodies through innovative technologies, has launched its Next Generation Human Antibody Discovery Platform. AbTherx’s novel transgenic mouse technology, Atlas Mice, includes a clinically validated bispecific antibody format, equivalent to a native antibody, and a long CDR3 antibody, using native human sequences, which improves results against challenging targets such as GPCRs and ion channels. AbTherx is also increasing access to transgenic mice expressing full human antibody diversity. Through technology licensing and research collaborations, AbTherx partners with drug developers of all sizes to overcome the most demanding challenges for advancing innovative medicines. With more than 100 years of overall experience around Ab discovery and transgenic mouse technologies, AbTherx leadership team has developed the world’s most successful human antibody discovery platform, the HuMAb Mouse technology, responsib...